EY-002
Neovascular Age‑Related Macular Degeneration
Phase 1Active
Key Facts
About EyeYon Medical
Israeli biotech delivering sustained‑release ocular implants for retinal disease therapy.
View full company profileTherapeutic Areas
Other Neovascular Age‑Related Macular Degeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| Ranibizumab Biosimilar | Biomm | Approved |
| IBI302 | AP Biosciences | Phase 3 |